Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Triamcinolone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 8/20 | 0.68 |
| ▸ | HIF1A | Q16665 | 10/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 8/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.68 |
| ▸ | PGR | P06401 | 5/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.68 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.68 |
| ▸ | LMNA | P02545 | 3/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.68 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.68 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.68 |
| ▸ | BLM | P54132 | 1/20 | 0.68 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.66 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.66 |
| ▸ | SHBG | P04278 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | AR | P10275 | 3/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dexamethasone SCHEMBL322760 | 0.95 | HIF1A (0.69) | HIF1AHSD17B10CYP3A4NR3C1PGR | |
| Tixocortol Pivalate SCHEMBL4455114 | 0.93 | HIF1A (0.60) | HIF1AHSD17B10CYP3A4NR3C1PGR | |
| Betamethasone SCHEMBL28086533 | 0.91 | HIF1A (0.66) | HIF1AHSD17B10CYP3A4NR3C1PGR | |
| Triamcinolone SCHEMBL5151654 | 0.91 | HIF1A (0.72) | HIF1AHSD17B10CYP3A4NR3C1PGR | |
| Triamcinolone SCHEMBL9837854 | 0.88 | HIF1A (0.66) | HIF1AHSD17B10CYP3A4NR3C1PGR | |
| Hydrocortisone Phosphoric Acid SCHEMBL8190634 | 0.87 | HIF1A (0.66) | HIF1AHSD17B10CYP3A4NR3C1PGR | |
| Triamcinolone SCHEMBL5146078 | 0.87 | NR3C1 (0.75) | HIF1AHSD17B10CYP3A4NR3C1PGR | |
| Hydrocortisone SCHEMBL8190636 | 0.86 | NR3C1 (0.57) | HIF1AHSD17B10CYP3A4NR3C1PGR | |
| Cortisone SCHEMBL14862506 | 0.86 | HSD17B10 (0.60) | HIF1AHSD17B10CYP3A4NR3C1PGR | |
| Dexamethasone SCHEMBL4586353 | 0.85 | HIF1A (0.56) | HIF1AHSD17B10CYP3A4NR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11541000-B2 | Pharmaceutical cream compositions of oxymetazoline and methods of use | EPI HEALTH, LLC (US) | 2023-01-03 | — | — | US | disclosed |
| US-20210069186-A1 | METHOD AND THERAPEUTIC/COSMETIC TOPICAL COMPOSITIONS FOR THE TREATMENT OF ROSACEA AND SKIN ERYTHEMA USING A1-ADRENOCEPTOR AGONISTS | EPI HEALTH, LLC | 2021-03-11 | — | — | US | disclosed |
| EP-3181121-B1 | PHARMACEUTICAL CREAM COMPOSITIONS COMPRISING OXYMETAZOLINE TO TREAT ROSACEA | EPI HEALTH LLC (US) | 2020-10-28 | — | — | EP | disclosed |
| US-20200276108-A1 | PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE | EPI HEALTH, LLC | 2020-09-03 | — | — | US | disclosed |
| US-20200188517-A1 | PHARMACEUTICAL CREAM COMPOSITIONS AND METHODS OF USE | EPI HEALTH, LLC | 2020-06-18 | — | — | US | disclosed |
| US-20200054608-A1 | ALPHA ADRENERGIC AGONISTS FOR THE TREATMENT OF TISSUE TRAUMA | ALLERGAN INC (US) | 2020-02-20 | — | — | US | disclosed |
| EP-3498299-A1 | COMPOSITIONS AND METHODS FOR TREATING PURPURA | Aclaris Therapeutics, Inc. (US) | 2019-06-19 | — | — | EP | disclosed |
| US-20190167566-A1 | PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE | EPI HEALTH, LLC | 2019-06-06 | — | — | US | disclosed |
| EP-2675449-B1 | PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE FOR TREATING SYMPTOMS OF ROSACEA | ACLARIS THERAPEUTICS INC (US) | 2019-04-24 | — | — | EP | disclosed |
| US-20190008857-A1 | Method and Therapeutic/Cosmetic Topical Compositions for the Treatment of Rosacea and Skin Erythema Using A1-Adrenoceptor Agonists | ASPECT PHARMACEUTICALS LLC | 2019-01-10 | — | — | US | disclosed |
| US-20110027201-A1 | METHOD AND THERAPEUTIC/COSMETIC TOPICAL COMPOSITIONS FOR THE TREATMENT OF ROSACEA AND SKIN ERYTHEMA USING A1-ADRENOCEPTOR AGONISTS | VICEPT THERAPEUTICS, INC. (US) | 2011-02-03 | — | — | US | disclosed |
| US-7812049-B2 | alpha 1-adrenoceptor agonists for treating skin redness; oxymetazoline hydrochloride | VICEPT THERAPEUTICS, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-20100233109-A1 | METHOD AND THERAPEUTIC/COSMETIC TOPICAL COMPOSITIONS FOR THE TREATMENT OF ROSACEA AND SKIN ERYTHEMA USING A1-ADRENOCEPTOR AGONISTS | VICEPT THERAPEUTICS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| EP-2207424-A1 | COMPOSITIONS AND METHODS FOR TREATING PURPURA | Vicept Therapeutics, Inc. (US) | 2010-07-21 | — | — | EP | disclosed |
| US-20090318410-A1 | IMIDAZOPYRIDAZINES AS LIPID KINASE INHIBITORS | NOVARTIS AG | 2009-12-24 | — | — | US | disclosed |
| WO-2009065116-A1 | COMPOSITIONS AND METHODS FOR TREATING PURPURA | ASPECT PHARMACEUTICALS LLC (US) | 2009-05-22 | — | — | WO | disclosed |
| US-20090130027-A1 | COMPOSITIONS AND METHODS FOR TREATING PURPURA | ASPECT PHARMACEUTICALS LLC (US) | 2009-05-21 | — | — | US | disclosed |
| US-20050165079-A1 | alpha 1-adrenoceptor agonists for treating skin redness; oxymetazoline hydrochloride | EPI HEALTH, LLC | 2005-07-28 | — | — | US | disclosed |
| EP-0835098-A1 | NEW, STABLE MEDICINAL COMPOSITIONS FOR GENERATING PROPELLANT-FREE AEROSOLS | BOEHRINGER INGELHEIM KG (DE) | 1998-04-15 | — | — | EP | disclosed |
| WO-1997001329-A1 | NEW, STABLE MEDICINAL COMPOSITIONS FOR GENERATING PROPELLANT-FREE AEROSOLS | BOEHRINGER INGELHEIM KG (DE) | 1997-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165079-A1 | alpha 1-adrenoceptor agonists for treating skin redness; oxymetazoline hydrochloride | ADRA1A, ADRA1D, ADRA2A | NR3C1 468/4885HIF1A 490/4885HSD17B10 1968/4885 |
| US-20200276108-A1 | PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE | PDE3A, TREH, VEGFA | NR3C1 1624/4885HIF1A 336/4885HSD17B10 1777/4885 |
| US-20200054608-A1 | ALPHA ADRENERGIC AGONISTS FOR THE TREATMENT OF TISSUE TRAUMA | ADRB3, ADRB2, ADRB1 | NR3C1 1650/4885HIF1A 367/4885HSD17B10 2782/4885 |
| US-20200188517-A1 | PHARMACEUTICAL CREAM COMPOSITIONS AND METHODS OF USE | CUTA, KRT18, IL17A | NR3C1 736/4885HIF1A 1029/4885HSD17B10 3359/4885 |
| US-11541000-B2 | Pharmaceutical cream compositions of oxymetazoline and methods of use | PDE3A, TREH, VEGFA | NR3C1 1624/4885HIF1A 336/4885HSD17B10 1777/4885 |
| US-20190167566-A1 | PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE | PDE3A, TREH, VEGFA | NR3C1 1624/4885HIF1A 336/4885HSD17B10 1777/4885 |
| US-20090318410-A1 | IMIDAZOPYRIDAZINES AS LIPID KINASE INHIBITORS | PI4KA, PIK3CA, PIK3CB | NR3C1 2437/4885HIF1A 2841/4885HSD17B10 1586/4885 |
| US-20210069186-A1 | METHOD AND THERAPEUTIC/COSMETIC TOPICAL COMPOSITIONS FOR THE TREATMENT OF ROSACEA AND SKIN ERYTHEMA USING A1-ADRENOCEPTOR AGONISTS | ADRA1A, ADRA2A, ADRA1D | NR3C1 613/4885HIF1A 721/4885HSD17B10 1456/4885 |
| US-20110027201-A1 | METHOD AND THERAPEUTIC/COSMETIC TOPICAL COMPOSITIONS FOR THE TREATMENT OF ROSACEA AND SKIN ERYTHEMA USING A1-ADRENOCEPTOR AGONISTS | ADRA1A, ADRA2A, ADRA1D | NR3C1 613/4885HIF1A 721/4885HSD17B10 1456/4885 |
| US-20100233109-A1 | METHOD AND THERAPEUTIC/COSMETIC TOPICAL COMPOSITIONS FOR THE TREATMENT OF ROSACEA AND SKIN ERYTHEMA USING A1-ADRENOCEPTOR AGONISTS | ADRA1A, ADRA2A, ADRA1D | NR3C1 613/4885HIF1A 721/4885HSD17B10 1456/4885 |
| US-20190008857-A1 | Method and Therapeutic/Cosmetic Topical Compositions for the Treatment of Rosacea and Skin Erythema Using A1-Adrenoceptor Agonists | ADRA1A, ADRA2A, ADRA1D | NR3C1 613/4885HIF1A 721/4885HSD17B10 1456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.